Noile-Immune Biotech Future Growth
Future criteria checks 0/6
Noile-Immune Biotech's earnings are forecast to decline at 15.5% per annum while its annual revenue is expected to grow at 0.7% per year. EPS is expected to decline by 15.1% per annum.
Key information
-15.5%
Earnings growth rate
-15.1%
EPS growth rate
| Biotechs earnings growth | 9.3% |
| Revenue growth rate | 0.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Sep 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 319 | -1,483 | N/A | N/A | 1 |
| 12/31/2025 | 319 | -1,233 | N/A | N/A | 1 |
| 12/31/2024 | 319 | -903 | N/A | N/A | 1 |
| 6/30/2024 | 307 | -980 | -975 | -975 | N/A |
| 3/31/2024 | 310 | -976 | N/A | N/A | N/A |
| 12/31/2023 | 316 | -1,130 | -873 | -873 | N/A |
| 9/30/2023 | 319 | -1,268 | N/A | N/A | N/A |
| 12/31/2022 | 625 | -386 | N/A | N/A | N/A |
| 12/31/2021 | 100 | -795 | N/A | N/A | N/A |
| 12/31/2020 | 97 | -636 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4893 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4893 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4893 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4893's revenue (0.7% per year) is forecast to grow slower than the JP market (4.1% per year).
High Growth Revenue: 4893's revenue (0.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4893's Return on Equity is forecast to be high in 3 years time